Secernin 3 抗体
Quick Overview for Secernin 3 抗体 (ABIN7257856)
抗原
See all Secernin 3 (SCRN3) 抗体适用
宿主
克隆类型
标记
应用范围
- 
    - 
                                            产品特性
- Polyclonal Antibody
- 
                                            纯化方法
- Affinity purification
- 
                                            免疫原
- Recombinant fusion protein of human SCRN3 (NP_078859.2).
- 
                                            亚型
- IgG
 
- 
                                            
- 
    
- 
    - 
                                            应用备注
- WB 1:500-1:2000 IF 1:50-1:200
- 
                                            限制
- 仅限研究用
 
- 
                                            
- 
    - 
                                            状态
- Liquid
- 
                                            浓度
- 1 mg/mL
- 
                                            缓冲液
- PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3
- 
                                            储存液
- Sodium azide
- 
                                            注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 
                                            储存条件
- -20 °C
- 
                                            储存方法
- Store at -20°C. Avoid freeze / thaw cycles.
 
- 
                                            
- 
    - Secernin 3 (SCRN3)
- 
                                            别名
- SCRN3
- 
                                            背景
- SCRN3 (Secernin 3) is a Protein Coding gene. Diseases associated with SCRN3 include Bile Acid Synthesis Defect, Congenital, 1 and Acrodysostosis. Gene Ontology (GO) annotations related to this gene include dipeptidase activity. An important paralog of this gene is SCRN2.
- 
                                            分子量
- 
                        Observed_MW: 48 kDa Calculated_MW: 47 kDa/48 kDa 
- 
                                            基因ID
- 79634
- 
                                            UniProt
- Q0VDG4
 抗原
- 
                    
 
                                     
                                     
                                    